New York: Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Has Just Had Its "Buy" Rating Reiterated by Piper Jaffray. Shares now Have a $202 Target | Thorold News - Thorold News
New York: Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Has Just Had Its "Buy" Rating Reiterated by Piper Jaffray. Shares now Have a $202 Target | Thorold News Thorold News
Investors sentiment decreased to 1.28 in Q3 2018. Its down 0.24, from 1.52 in 2018Q2. It is negative, as 34 investors sold Jazz Pharmaceuticals plc shares.
Comments
Post a Comment